scholarly journals Insulin-Mediated Glucose Metabolism: An Atherogenic Lipid Profile of Fructose Consumption

2018 ◽  
Vol 2 (2) ◽  
pp. 01-02
Author(s):  
Elizabeth Kagotho
Keyword(s):  
Lipid Profile ◽  
Positive Energy ◽  
Sweetened Beverages ◽  
Atherogenic Lipid Profile ◽  
High Fructose ◽  
Short And Long Term ◽  
Postprandial Triacylglycerol ◽  
Atherogenic Lipid ◽  
Long Term Studies

Our laboratory has investigated two hypotheses regarding the effects of fructose consumption: 1) The endocrine effects of fructose consumption favor a positive energy balance, and 2) Fructose consumption promotes the development of an atherogenic lipid profile. In previous short- and long-term studies, we demonstrated that consumption of fructose-sweetened beverages with 3 meals results in lower 24-hour plasma concentrations of glucose, insulin, and leptin in humans compared with consumption of glucose-sweetened beverages. We have also tested whether prolonged consumption of high-fructose diets could lead to increased caloric intake or decreased energy expenditure, thereby contributing to weight gain and obesity. Results from a study conducted in rhesus monkeys produced equivocal results. Carefully controlled and adequately powered long-term studies are needed to address these hypotheses. In both short- and long-term studies we demonstrated that consumption of fructose-sweetened beverages substantially increases postprandial triacylglycerol concentrations compared with glucose-sweetened beverages. In the long-term studies, apolipoproteinB concentrations were also increased in subjects consuming fructose, but not those consuming glucose. Data from a short-term study comparing consumption of beverages sweetened with fructose, glucose, high fructose corn syrup (HFCS) and sucrose, suggest that HFCS and sucrose increase postprandial triacylglycerol to an extent comparable to that induced by 100% fructose alone. Increased consumption of fructose-sweetened beverages along with increased prevalence of obesity, metabolic syndrome, and type 2 diabetes underscore the importance of investigating the metabolic consequences fructose consumption in carefully controlled experiments.

scholarly journals Insulin-Mediated Glucose Metabolism: An Atherogenic Lipid Profile of Fructose Consumption

2018 ◽  
Vol 2 (2) ◽  
pp. 01-02
Author(s):  
Elizabeth Kagotho
Keyword(s):  
Lipid Profile ◽  
Positive Energy ◽  
Sweetened Beverages ◽  
Atherogenic Lipid Profile ◽  
High Fructose ◽  
Short And Long Term ◽  
Postprandial Triacylglycerol ◽  
Atherogenic Lipid ◽  
Long Term Studies

Our laboratory has investigated two hypotheses regarding the effects of fructose consumption: 1) The endocrine effects of fructose consumption favor a positive energy balance, and 2) Fructose consumption promotes the development of an atherogenic lipid profile. In previous short- and long-term studies, we demonstrated that consumption of fructose-sweetened beverages with 3 meals results in lower 24-hour plasma concentrations of glucose, insulin, and leptin in humans compared with consumption of glucose-sweetened beverages. We have also tested whether prolonged consumption of high-fructose diets could lead to increased caloric intake or decreased energy expenditure, thereby contributing to weight gain and obesity. Results from a study conducted in rhesus monkeys produced equivocal results. Carefully controlled and adequately powered long-term studies are needed to address these hypotheses. In both short- and long-term studies we demonstrated that consumption of fructose-sweetened beverages substantially increases postprandial triacylglycerol concentrations compared with glucose-sweetened beverages. In the long-term studies, apolipoproteinB concentrations were also increased in subjects consuming fructose, but not those consuming glucose. Data from a short-term study comparing consumption of beverages sweetened with fructose, glucose, high fructose corn syrup (HFCS) and sucrose, suggest that HFCS and sucrose increase postprandial triacylglycerol to an extent comparable to that induced by 100% fructose alone. Increased consumption of fructose-sweetened beverages along with increased prevalence of obesity, metabolic syndrome, and type 2 diabetes underscore the importance of investigating the metabolic consequences fructose consumption in carefully controlled experiments.

scholarly journals Effect of Pericampylus glaucus on plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats

2016 ◽  
Vol 11 (1) ◽  
pp. 200 ◽  
Author(s):  
Muhammad Kifayatullah ◽  
Pinaki Sengupta
Keyword(s):  
Lipid Profile ◽  
Plasma Glucose ◽  
Glucose Concentration ◽  
Ethanolic Extract ◽  
Diabetic Rats ◽  
Plasma Glucose Concentration ◽  
Short And Long Term ◽  
Different Doses ◽  
Long Term Studies

<p class="Abstract">The purpose of this study was to evaluate the effects of <em>Pericampylus glaucus</em> extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. The ethanolic extract were administered orally at three different doses (400, 600 and 800 mg/kg) and glibenclamide (20 mg/kg p.o.) for 21 days after 72 hours of streptozotocin injection. During the short- and long-term studies, the extract was found to possess significant (p&lt;0.01, p&lt;0.001) anti-diabetic activity in normal and diabetic rats compared with untreated normal and untreated diabetic group. It also caused reduction in the level of total cholesterol, triglyceride, and LDL etc. and improvement in the HDL level compared with untreated diabetic rats. Reduction in the fasting blood sugar, cholesterol, triglyceride, urea, LDL, creatinine levels and improvement in the HDL by<em> P. glaucus</em> indicates that plant has anti-diabetic activity along with anti hyperlipidemic efficacy and provides a scientific rationale for the use.</p><p> </p>

Alterationsinarterial pressureinpatients with Type1diabetes are associated with long-term poor metabolic control andamore atherogenic lipid profile

2010 ◽  
Vol 34 (2) ◽  
pp. e24-e29 ◽  
Author(s):  
F. J. Vílchez-López ◽  
F. Carral-Sanlaureano ◽  
C. Coserria-Sánchez ◽  
A. Nieto ◽  
S. Jiménez ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Metabolic Control ◽  
Poor Metabolic Control ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy

2019 ◽  
Vol 3 (8) ◽  
pp. 1503-1517 ◽  
Author(s):  
Alexandra B Kinzer ◽  
Robert D Shamburek ◽  
Marissa Lightbourne ◽  
Ranganath Muniyappa ◽  
Rebecca J Brown
Keyword(s):  
Insulin Resistance ◽  
High Density Lipoprotein ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Profile ◽  
Cvd Risk ◽  
Lipoprotein Particles ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

Abstract Context Patients with lipodystrophy have dyslipidemia and insulin resistance. Leptin treatment with metreleptin in lipodystrophy decreases insulin resistance and lowers triglycerides without changing high-density lipoprotein. Detailed measurement of lipoprotein particles with nuclear magnetic resonance (NMR) spectroscopy can offer insights into cardiovascular disease (CVD) risk and lipid metabolism beyond a standard lipid panel. We hypothesized that patients with lipodystrophy would have a more atherogenic lipid profile than controls at baseline, which would be ameliorated with metreleptin treatment. Objective To characterize the lipoprotein profile in patients with lipodystrophy compared with controls and to evaluate effects of metreleptin treatment. Design, Setting, Patients, and Intervention Patients with lipodystrophy (N = 17) were studied before and after metreleptin for 2 weeks and 6 months and compared with 51 insulin-sensitive sex-matched controls. Main Outcome Measures Lipoprotein profiles were measured by NMR with the LP4 deconvolution algorithm, which reports triglyceride-rich lipoprotein particles (TRLPs), high-density lipoprotein particles (HDLPs), and low-density lipoprotein particles (LDLPs). Results Patients with lipodystrophy had elevated large TRLPs and smaller HDLPs and LDLPs compared with controls. Five patients with lipodystrophy had chylomicrons, compared with zero controls. Metreleptin decreased the size and concentration of TRLPs, eliminated chylomicrons in all but one patient, decreased LDLPs, and increased LDLP size. Metreleptin treatment did not have major effects on HDLPs. Conclusions Patients with lipodystrophy had an atherogenic lipoprotein profile at baseline consistent with elevated CVD risk, which improved after metreleptin treatment. The presence of fasting chylomicrons in a subset of patients with lipodystrophy suggests saturation of chylomicron clearance by lipoprotein lipase.

Short- and long-term studies of sediment dynamics in a small humid mountain Mediterranean basin with badlands

Geomorphology ◽  
2013 ◽  
Vol 196 ◽  
pp. 242-251 ◽  
Author(s):  
F. Gallart ◽  
N. Pérez-Gallego ◽  
J. Latron ◽  
G. Catari ◽  
N. Martínez-Carreras ◽  
...  
Keyword(s):  
Mediterranean Basin ◽  
Sediment Dynamics ◽  
Short And Long Term ◽  
Long Term Studies

W02-O-002 The APOB-516C/T polymorphism isassociated with a more atherogenic lipid profile in males independently of the consumption of dietary fat

2005 ◽  
Vol 6 (1) ◽  
pp. 7
Author(s):  
P. Perez-Martinez ◽  
J. Lopez-Miranda ◽  
A. Lozano ◽  
J.A. Moreno ◽  
C. Bellido ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Dietary Fat ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile

2005 ◽  
Vol 46 (11) ◽  
pp. 2398-2404 ◽  
Author(s):  
Gerly M. van der Vleuten ◽  
Lambertus J. H. van Tits ◽  
Martin den Heijer ◽  
Heidi Lemmers ◽  
Anton F. H. Stalenhoef ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Familial Combined Hyperlipidemia ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals The Current Dietary Risk Assessment of Chemicals in Food Underestimates the Actual Risk

2019 ◽  
Vol 73 (10) ◽  
pp. 832-834
Author(s):  
Jürg A. Zarn ◽  
H. Christoph Geiser
Keyword(s):  
Daily Intake ◽  
Added Value ◽  
Toxic Substances ◽  
Dietary Risk ◽  
Short And Long Term ◽  
Exposure Levels ◽  
Design Factors ◽  
Dietary Risk Assessment ◽  
Long Term Studies

Dietary risk assessments (DRA) help determine safe exposure levels of toxic substances in food. Of these, Acceptable Daily Intake (ADI), derived from No Observed Adverse Effect Levels (NOAEL) of long-term toxicity studies, is compared to exposure estimates using lifetime-averaged food intakes. These estimates ignore intermittent high exposures exceeding the ADI; toxic effects of such exposures are considered irrelevant, on the assumption that toxic potency increases with exposure duration, which would be reflected by decreasing NOAELs. However, our statistical analysis of thousands of animal toxicology studies shows that NOAELs after short- and long-term exposure are similar if study design factors are considered. Thus, the short- and long-term potency effects of chemicals are similar. Hence, a short-term toxic effect is generally ignored in current DRA. It accounts for lifetime-averaged but not intermittent high food intakes and, therefore, must be revised. Additionally, there is no added value of long-term studies for ADI derivation.

Sign in / Sign up

Export Citation Format

Share Document